Department of Structural and Functional Biology, Biology Institute, State University of Campinas, Campinas, SP, Brazil.
Adv Exp Med Biol. 2020;1276:15-25. doi: 10.1007/978-981-15-6082-8_2.
In this chapter, we present the major advances in CETP research since the detection, isolation, and characterization of its activity in the plasma of humans and several species. Since CETP is a major modulator of HDL plasma levels, the clinical importance of CETP activity was recognized very early. We describe the participation of CETP in reverse cholesterol transport, conflicting results in animal and human genetic studies, possible new functions of CETP, and the results of the main clinical trials on CETP inhibition. Despite major setbacks in clinical trials, the hypothesis that CETP inhibitors are anti-atherogenic in humans is still being tested.
在这一章中,我们介绍了自 CETP 在人类和几种物种的血浆中被检测、分离和特性鉴定以来,在 CETP 研究方面取得的主要进展。由于 CETP 是 HDL 血浆水平的主要调节剂,因此 CETP 活性的临床重要性很早就得到了认识。我们描述了 CETP 在胆固醇逆向转运中的作用,动物和人类遗传研究中的矛盾结果,CETP 的可能新功能,以及 CETP 抑制的主要临床试验结果。尽管临床试验遭遇了重大挫折,但 CETP 抑制剂在人类中具有抗动脉粥样硬化作用的假设仍在被检验。